DB
SLN

Dmitry Balyasny’s Silence Therapeutics SLN Stock Holding History

Dmitry Balyasny’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.71M Buy
+610,980
New +$4.3M 0.01% 1240

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Dmitry Balyasny's SLN Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Silence Therapeutics (SLN) in Q2 2026: 610,980 shares worth $6.71M. The stake represents 0.01% of the portfolio and ranks #1240 among its holdings.

72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Dmitry Balyasny held 610,980 shares of Silence Therapeutics worth $6.71M as of Q2 2026.
  • Silence Therapeutics was a new Dmitry Balyasny position in Q2 2026.
  • Silence Therapeutics made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1240 holding.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.